In this section, we review evidence of the involvement of autophagy, endoplasmic reticulum stress, mitochondrial dysfunction, and macrophage polarization in UC pathology
40 However, the legal protection afforded by a skinny label is fragile
The good news is that by addressing one, you may see improvements in the other
In doing so, this review seeks to clarify context-specific mechanisms, identify areas of translational opportunity, and outline how targeting NETs could reshape future therapeutic strategies
Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Historic and Forecast (2020-2030) 8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment, 2020-2030 (USD Million & CAGR) 8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Key Factors 8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Value Assessment 8.5 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market: Market Dynamics 8.6 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Distribution Channel 8.6.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Distribution Channel Overview 8.6.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Clinics, By Value, 2020H-2030F (USD Million & CAGR) 8.6.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Ambulatory Surgical Centers, By Value, 2020H-2030F (USD Million & CAGR) 8.6.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Hospitals, By Value, 2020H-2030F (USD Million & CAGR) 8.7 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By Route of Administration 8.7.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By Route of Administration Overview 8.7.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR) 8.7.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR) 8.8 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Segmentation: By End-Use 8.8.1 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market, By End-Use Overview 8.8.2 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Type 2 Diabetes, By Value, 2020H-2030F (USD Million & CAGR) 8.8.3 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By NASH, By Value, 2020H-2030F (USD Million & CAGR) 8.8.4 Middle East & Africa Glucagon-Like Peptide 1 (GLP-1) Agonist Market Size, By Obesity, By Value, 2020H-2030F (USD Million & CAGR) 9
2024;10:e756
